Hyperfine terminates CMO/CSO Khan Siddiqui; transitions to consultant

Hyperfine, Inc.

Khan Siddiqui terminated as Chief Medical Officer and Chief Strategy Officer effective September 30, 2023.
Will continue as consultant at $300/hour; salary paid through separation date.
Outstanding equity awards to continue vesting during consulting period under 2021 Equity Plan.
Separation agreement includes $500 payment, standard release, and non-disparagement.
No replacement named for the dual roles.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Khan Siddiqui

Chief Medical Officer and Chief Strategy Officer

HYPR · Hyperfine, Inc.

Effective: 2023-09-30
Filed: October 3, 2023, 7:59 PM ET

On September 27, 2023, Hyperfine, Inc. (the “Company”) terminated Khan Siddiqui, M.D.’s part-time employment as the Company’s Chief Medical Officer and Chief Strategy Officer, effective September 30, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Khan Siddiqui was terminated as Chief Medical Officer and Chief Strategy Officer at Hyperfine, Inc..

Action: terminated
Role: Chief Medical Officer and Chief Strategy Officer

Exact text from the filing

On September 27, 2023, Hyperfine, Inc. (the “Company”) terminated Khan Siddiqui, M.D.’s part-time employment as the Company’s Chief Medical Officer and Chief Strategy Officer, effective September 30, 2023

View on SEC.gov

Hyperfine, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-051513

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.